



Curriculum Vitae

Aron Schlau, M.D., FACP

aron.schlau@yahoo.com

727-785-4540 ext. 2312

Education:	Graduated 1981	Doctor of Medicine (MD) Center of Technical Studies Santa Domingo, Dominican Republic
Postgraduate Training:	1982-1985	Internal Medicine Residency The LaGuardia Hospital Forest Hills, New York, NY, USA
	1990	Passed Board Certification Exam (Internal Medicine)
Professional Experience:	2020	President of the Pinellas County Medical Association
	2018	Delegate for Pinellas County Medical Association
	2017 to date	Fellow of the American College of Physicians
	2013	Medical Director Lakeside Oaks Nursing Home, Dunedin, Fl.
	2011	Preceptor Long Island University/C.W. Post Campus

Palm Harbor Medical Associates
3820 Tampa Road, #102 &202
Palm Harbor, Florida. 34684

Sunset Point Medical Associates
1969 Sunset Point Road #115
Clearwater, Florida. 33765

Tarpon Springs Medical Associates
651 East Tarpon Avenue
Tarpon Springs, Florida. 34689

Hillsborough Medical Associates
7519 Paula Drive
Tampa, Florida. 33615

Professional Experience (cont.):

1986 to present

President/Practice Owner

Palm Harbor Medical Associates

3820 Tampa Road, Ste 102 and 202

Palm Harbor, Florida. 34684

Sunset Point Medical Associates

Tarpon Springs Medical Associates

Hillsborough Medical Associates

Avalon Medical Spa/Tarpon Springs/Tampa

Feb-2013

Laser Licensing and Certification

2012-2013

Medical Consultant for television's

ABC Action News "Consumer Update"

2001-2003

Weekly Informative Call In Talk Show

relevant medical news, interviews, facts,
available to the public

2003

Author of "The Prescription Medication
Savings Guide"

1986-1988

Physician Review Committee

Physician Review Organization

1992- 1994

Medical Director

Tarpon Springs Convalescent Center

1990-1995

Medical Director

Palm Harbor Medical Associates
3820 Tampa Road, #102 &202
Palm Harbor, Florida. 34684

Sunset Point Medical Associates
1969 Sunset Point Road #115
Clearwater, Florida. 33765

Tarpon Springs Medical Associates
651 East Tarpon Avenue
Tarpon Springs, Florida. 34689

Hillsborough Medical Associates
7519 Paula Drive
Tampa, Florida. 33615

Hacienda House

1996-1997

Preceptor of Medical Students

University of South Florida

College of Medicine, Tampa, Fl.

1997-1998

Medical Director

Normal Life (currently ResCare)

1996-1999

Medical Director

Home Health Corporation of America

1992-1999

Medical Director

Tarpon Health Care

Professional Licensure

Current

Florida ME47065

Professional Organizations

1998-2001

Southern Medical Association

1998-2001

Southern Association for Primary Care

1990-present

American Medical Association

1996

American Medical Directors Association

2004-present

Pinellas County Medical Association

Research Experience:

1994-1997

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

2000

An Open Label Trial to Evaluate the Efficacy and Safety of test article XXX Once-Daily, an Ace-Inhibitor for the Treatment of **Hypertension**

2001

An Open, Randomized, Parallel-Group, Multi-Center Trial to Compare a Stratified Care Treatment Regimen Based on Migraine Disability (MIDAS grade) Versus Standard Therapy for the Acute Treatment of **Migraine Headache**.

A Randomized, Open-Label, Multi-Center Trial of the Safety and Effectiveness of Oral test article xxx and Test article xxx in Outpatients with **Respiratory Tract Infections** in Usual Care Settings Ongoing test article xxx Alone and in Combination with test article xxx Global Endpoint Trial: A Large Simple, Randomized Trial of an Angiotensin II Receptor and an Ace-Inhibitor, in Subjects at **High Risk for Cardiovascular Events**

2002

A Multi-Center Prospective, Randomized, Double-Blind, Parallel-Group Study Comparing the Effects of Test article xxx and test article xxx on Systolic Blood Pressure and Pulse Pressure in Subjects with **Systolic Hypertension**.

A 12 week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation, of the Efficacy, Tolerability, and Safety of test article xxx in the Treatment of Young Adults with **Down Syndrome**

Impact of Point of Care Versus Laboratory Testing of Hemoglobin A1c and Intense Versus Standard Monitoring of Titration Algorithm Adherence on Glycemic Control in **Type 2 Diabetic** Subjects who are Inadequately Controlled on Oral Anti-Hyperglycemic Therapy and Starting test article xxx

2003

A Multi-Center, Case-Control, Clinical Study to Identify Genotypic Factors in Symptomatic Patients who Develop De Novo **Deep Vein Thrombosis (DVT)**

GOT, **Glycemic Optimization** Treatment Study (Phase IV)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison of test article xxx, Using Seated Trough Cuff Blood Pressure in Subjects with Stage 1 and Stage 2 **Hypertension**

TRANSCEND, A Randomized Assessment Trial of test article xxx in Ace-Inhibitor Intolerant Subjects with **Cardiovascular Disease**

2004

TREAT, A Trial to Reduce **Cardiovascular Events** with test article xxx Therapy

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of test article xxx in the **Primary Prevention of Cardiovascular Events** among Subjects with Low Levels of LDL Cholesterol and Elevated Levels of C-Reactive Protein

Glycemia Optimization Treatment: To Assess the Safety of Glucose Control as Measured by the Frequency of Severe Hypoglycemic Events Using Dosing Algorithms Based on Different Fasting Blood Glucose Goals with

test article xxx in Adult Individuals with **Type 2 Diabetes** Who have Not Achieved the Target A1c of less than 7% with Oral Hypoglycemic Agents

Efficacy and Safety of a Standard Titration Algorithm Coupled with Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm Alone, in Subjects with **Type 2 Diabetes** Initiating test article xxx Therapy

A Randomized, Double-Blind, Parallel-Group, Multi-Center Study to Compare Clinical Health Outcomes of test article xxx in Outpatients with **Community-Acquired Lower Respiratory Tract Infections**

A Phase III, Randomized, Three-Arm, Double-Blind, Parallel-Group, Multi-Center Trial to Evaluate the Safety and efficacy of test article xxx in Combination with test article xxx, in Subjects with **Type 2 Diabetes Mellitus** who Have Inadequate Glycemic Control on test article xxx Alone

2005

A Randomized, Double-Blind, Placebo-Controlled, Forced Titration, Phase IV Study Comparing test article xxx Versus test article xxx Taken Orally for 8 Weeks in Subjects With **Stage I or Stage II Hypertension**

SANCTURA: A Study to Evaluate Control of Urinary Symptoms Resulting From **Over-Active Bladder**

2006

A Study To Evaluate The Safety And Efficacy Of Pregabalin In Patients With Painful **Diabetic Peripheral Neuropathy (DPN)**

A Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study on **Extended VTE** Prophylaxis in Acutely Ill Medical Subjects with Prolonged Immobilization

A Randomized, Single-Blind, Placebo-Controlled, 4 Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects with **Chronic Kidney Disease not Requiring Dialysis**.

2007

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including **Bleeding and Symptomatic Ulcer Disease**.

A Multicenter, Randomized, Double-Blind, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy, and Safety of Once-Weekly Subcutaneous Biotinylated Idraparinux with Oral Adjusted Dose Warfarin in the **Prevention of Stroke and Systemic Thromboembolic Events in Patients with Atrial Fibrillation**

A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-center, Event Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily oral test article xxx With Adjusted Dose

oral test article xxx for the **Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Vascular Atrial Fibrillation**

2008

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with **Secondarily-Infected Traumatic Lesions**.

A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial of GI Safety of test article xxx Compared to Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in **Osteoarthritis** Subjects

A Phase III Trial and Extension for Subjects with **resistant Hypertension**

A 16-week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of test article xxx With test article xxx as reference in Subjects with **Type 2 Diabetes**

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase III Efficacy and Safety Study of test article xxx Compared to test article xxx to Reduce Incidence of upper Gastrointestinal Events Including **Bleeding and Symptomatic Ulcer Disease**

A Multi-Center, Randomized, double-Blind, Assessor Blind, Non-Inferiority Study Comparing the Safety of Once-Weekly Subcutaneous test article xxx with Oral Adjusted-Dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Subjects with **Atrial Fibrillation**

A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by **Osteoarthritis of the Knee**, in a 13-week, Double-blind, Randomized Study

2011

A Phase III, Randomised, Double-Blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Test Article Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With **Type II Diabetes**.

2012

A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed-Dose Combination in Patients With Stage 1 or 2 Essential **Hypertension**

A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of two Doses of Intra-Articular Injection of Study Drug in Adults with pain due to **osteoarthritis of the knee**.

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with XXX in Addition to Standard of Care in Subjects with **Type 2 Diabetes and Acute Coronary Syndrome**

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of XXX in Subjects with **Type II Diabetes Mellitus**.

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 8 week Study to Evaluate the Safety and Efficacy of XXX and XXX Given as a Fixed-Dose Combination in Patients With Stage 1 or 2 Essential Hypertension.

2013

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease

A randomized, double-blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with **type 2 diabetes mellitus** and insufficient glycemic control

A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin compared to Add-On Therapy with Saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in Subjects with **Type 2 Diabetes** who have Inadequate Glycemic Control on Metformin Alone

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Metformin compared to Therapy with Placebo added to Saxagliptin in Combination with Metformin in Subjects with **Type 2 Diabetes** who have Inadequate Glycemic Control on Metformin and Saxagliptin

A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established **Peripheral Artery Disease**

A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate **Chronic Obstructive Pulmonary Disease** (COPD) and a history of or at increased risk for cardiovascular disease

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with **Type 2 Diabetes** with High Baseline HbA1c

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an **Acute Coronary Syndrome**

A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in subjects with **Type 2 Diabetes**

A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for **Type 2 Diabetes**

A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients with **Type 2 Diabetes**

2014

A Phase 3, Double-Blind, Placebo Controlled, International, Multicenter Study to Assess the Effect of AMG 145/Evolocumab on **Cognitive Function in Patients with Clinically Evident Cardiovascular Disease** and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (formoterol fumarate) Inhalation Solution in Subjects with **Chronic Obstructive Pulmonary Disease (COPD)**

Outcomes Registry for Better Informed Treatment of **Atrial Fibrillation II/ ORBIT-AF II**
RIVAROXAFEN; Phase 4

A Phase 4, 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with **Type 2 Diabetes** who have Inadequate Glycemic Control with Diet and Exercise

A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects with **Diabetic Kidney Disease**

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with **Type 2 Diabetes Mellitus**

A Phase 3b, Randomized, double-blind, parallel group, multicenter study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established **Peripheral Artery Disease**

2015

A Phase 3b, 26-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Trial with a Blinded 26-week Long-term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin in Combination with Metformin Compared to Sitagliptin in Combination with Metformin in Adult Patients with **Type 2 Diabetes** Who Have Inadequate Glycemic Control on Metformin Therapy Alone

A Phase 3b, 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Blinded 104-week Long-term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin in combination with Metformin Compared to Glimepiride in Combination with Metformin in Adult Patients with **Type 2 Diabetes** Who Have Inadequate Glycemic Control on Metformin Therapy Alone.

A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in subjects with **type 2 diabetes mellitus** Trial phase: 3b

PALM Registry Patient and Provider Assessment of **Lipid Management** Registry

2016

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Test Article on the Occurrence of Major Adverse Cardiovascular Events in **Overweight and Obese Subjects with Cardiovascular Disease**.

Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with **type 2 diabetes** inadequately controlled with metformin monotherapy and treated in a primary care setting.

A 26-week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 on Patients with **Type 2 Diabetes Mellitus**

Efficacy and safety of oral semaglutide versus placebo in subjects with **type 2 diabetes mellitus** treated with diet and exercise only

Efficacy in controlling glycaemia with Victoza (liraglutide) as an add-on to Metformin vs. OADs as an add-on To metformin after up to 104 weeks of treatment in subjects with **type 2 diabetes** inadequately controlled with metformin monotherapy and treated in a primary care setting.

A Phase 2, Double-Blind, Placebo-Controlled, 18 Week Trial of Investigational Dulaglutide Doses versus

Palm Harbor Medical Associates
3820 Tampa Road, #102 &202
Palm Harbor, Florida. 34684

Sunset Point Medical Associates
1969 Sunset Point Road #115
Clearwater, Florida. 33765

Tarpon Springs Medical Associates
651 East Tarpon Avenue
Tarpon Springs, Florida. 34689

Hillsborough Medical Associates
7519 Paula Drive
Tampa, Florida. 33615

Placebo in Patients with **Type 2 Diabetes** on Metformin Monotherapy

A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3b Trial with a Blinded 104-week Long-term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin in combination with Metformin Compared to Glimpiride in Combination with Metformin in Adult Patients with **Type 2 Diabetes** Who Have Inadequate Glycemic Control on Metformin Therapy Alone.

A 26-week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 on Patients with **Type 2 Diabetes Mellitus**

A 24-week, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of Toujeo® and Tresiba® in **insulin-naive patients with type 2 diabetes mellitus** not adequately controlled with oral antidiabetic drug(s) ± GLP-1 receptor agonist

A randomized, phase 4, two-arm, open-label, active-controlled, multicentre, multinational, parallel-group trial to assess Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with **type 2 diabetes** inadequately controlled with metformin monotherapy and treated in a primary care setting

2017

A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with **Type 2 Diabetes Mellitus**

A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Two Investigational Dulaglutide Doses versus Placebo in Patients with **Type 2 Diabetes** on Metformin Monotherapy

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea alone or in combination with Metformin in Patients with **Type 2 Diabetes** Who Have Inadequate Glycemic Control on a Sulfonylurea Alone or with Metformin

A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimpiride as Add-on Therapy to Metformin in Patients with **Type 2 Diabetes**

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 units/mL in Subjects with **Type 2 Diabetes Mellitus** Inadequately Treated with Basal Insulin with or without Oral Antidiabetic Drugs

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in **Overweight and Obese Subjects with Cardiovascular Disease**

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with **Chronic Heart Failure with Reduced Ejection Fraction**

2018-2019

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of **Overactive Bladder (OAB)** in Adult Female Subjects

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with **Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function**

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients with **Type 2 Diabetes Mellitus** Who Have Inadequate Glycemic Control